Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

Dong Wook Kim, Weon Kuu Chung, Dongoh Shin, Seongeon Hong, Sung Ho Park, Sung Yong Park, Kwangzoo Chung, Young Kyung Lim, Dongho Shin, Se Byeong Lee, Hyun ho Lee, Myonggeun Yoon

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Purpose: To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. Methods: IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). Results: The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. Conclusions: OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT.

Original languageEnglish
Article number47
JournalRadiation Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - 2013 Mar 4

Keywords

  • IMRT
  • OED
  • Radio-photoluminescence
  • Secondary dose
  • TOMOTHERAPY
  • VMAT

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer'. Together they form a unique fingerprint.

Cite this